This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chen, C.-G. Articles by Lo, H.-J. Search for Related Content PubMed PubMed Citation Articles by Chen, C.-G. Articles by Lo, H.-J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2004, p. 4505-4512, Vol. 48, No. 12
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.12.4505-4512.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

CaNdt80 Is Involved in Drug Resistance in Candida albicans by Regulating CDR1

Graduate Institute of Life Sciences, National Defense Medical Center,¹ Division of Clinical Research, National Health Research Institutes, Taipei,² Department of Biological Science and Technology, National Chiao Tung University, Hsinchu, Taiwan, Republic of China.³

Received 29 July 2004/ Returned for modification 18 August 2004/ Accepted 23 August 2004

Overexpression of CDR1, an efflux pump, is one of the major mechanisms contributing to drug resistance in Candida albicans. CDR1 p-lacZ was constructed and transformed into a Saccharomyces cerevisiae strain so that the lacZ gene could be used as the reporter to monitor the activity of the CDR1 promoter. Overexpression of CaNDT80, the C. albicans homolog of S. cerevisiae NDT80, increases the ß-galactosidase activity of the CDR1 p-lacZ construct in S. cerevisiae. Furthermore, mutations in CaNDT80 abolish the induction of CDR1 expression by antifungal agents in C. albicans. Consistently, the Candt80/Candt80 mutant is also more susceptible to antifungal drugs than the wild-type strain. Thus, the gene for CaNdt80 may be the first gene among the regulatory factors involved in drug resistance in C. albicans whose function has been identified.

This article has been cited by other articles:

• Manoharlal, R., Gaur, N. A., Panwar, S. L., Morschhauser, J., Prasad, R. (2008). Transcriptional Activation and Increased mRNA Stability Contribute to Overexpression of CDR1 in Azole-Resistant Candida albicans. Antimicrob. Agents Chemother. 52: 1481-1492 [Abstract] [Full Text]  
• Gulshan, K., Moye-Rowley, W. S. (2007). Multidrug Resistance in Fungi. Eukaryot Cell 6: 1933-1942 [Full Text]  
• Coste, A., Selmecki, A., Forche, A., Diogo, D., Bougnoux, M.-E., d'Enfert, C., Berman, J., Sanglard, D. (2007). Genotypic Evolution of Azole Resistance Mechanisms in Sequential Candida albicans Isolates. Eukaryot Cell 6: 1889-1904 [Abstract] [Full Text]  
• Dementhon, K., Iyer, G., Glass, N. L. (2006). VIB-1 Is Required for Expression of Genes Necessary for Programmed Cell Death in Neurospora crassa. Eukaryot Cell 5: 2161-2173 [Abstract] [Full Text]  
• Wang, J.-S., Yang, Y.-L., Wu, C.-J., Ouyang, K. J., Tseng, K.-Y., Chen, C.-G., Wang, H., Lo, H.-J. (2006). The DNA-binding domain of CaNdt80p is required to activate CDR1 involved in drug resistance in Candida albicans.. J Med Microbiol 55: 1403-1411 [Abstract] [Full Text]  
• Uko, S., Soghier, L. M., Vega, M., Marsh, J., Reinersman, G. T., Herring, L., Dave, V. A., Nafday, S., Brion, L. P. (2006). Targeted Short-Term Fluconazole Prophylaxis Among Very Low Birth Weight and Extremely Low Birth Weight Infants. Pediatrics 117: 1243-1252 [Abstract] [Full Text]  
• Coste, A., Turner, V., Ischer, F., Morschhauser, J., Forche, A., Selmecki, A., Berman, J., Bille, J., Sanglard, D. (2006). A Mutation in Tac1p, a Transcription Factor Regulating CDR1 and CDR2, Is Coupled With Loss of Heterozygosity at Chromosome 5 to Mediate Antifungal Resistance in Candida albicans. Genetics 172: 2139-2156 [Abstract] [Full Text]